瑞舒伐他汀与阿托伐他汀治疗高血压并低密度脂蛋白胆固醇升高患者临床疗效及其对靶器官功能影响的对比研究

Comparative Study for Clinical Effect and Impact on Target Organ Function of Hypertension Patients Complicated with Elevated LDL-C between Rosuvastatin and Atorvastatin

目的比较瑞舒伐他汀与阿托伐他汀治疗高血压并低密度脂蛋白胆固醇(LDL-C)升高患者的临床疗效及其对靶器官功能的影响。方法选取内蒙古医科大学附属医院老年病科2013年1月—2014年1月收治的高血压并LDL-C升高患者120例,随机分为对照组和观察组,每组60例。两组患者入院后均给予常规治疗,对照组患者在常规治疗基础上给予阿托伐他汀治疗,观察组患者在常规治疗基础上给予瑞舒伐他汀钙片治疗;两组患者均长期服药至随访结束。随访2年,比较两组患者治疗前后血脂指标〔总胆固醇(TC)、三酰甘油(TG)、LDL-C、高密度脂蛋白胆固醇(HDL-C)〕及颈动脉内膜中层厚度(IMT)、肾小球滤过率。结果治疗前两组患者TC、TG、LDL-C、HDL-C水平比较,差异无统计学意义(P>0.05);治疗后观察组患者TC、LDL-C水平低于对照组,HDL-C水平高于对照组(P<0.05),但两组患者TG水平比较,差异无统计学意义(P>0.05)。治疗前两组患者颈动脉IMT和肾小球滤过率比较,差异无统计学意义(P>0.05);治疗后观察组患者颈动脉IMT小于对照组,肾小球滤过率高于对照组(P<0.05)。结论瑞舒伐他汀治疗高血压并LDL-C升高患者的临床疗效优于阿托伐他汀,可更有效地改善患者血脂代谢、降低颈动脉IMT、提高肾小球滤过率,对靶器官功能的保护作用更佳。

Objective To compare the clinical effect and impact on target organ function of hypertension patients complicated with elevated LDL-C between rosuvastatin and atorvastatin. Methods From January 2013 to January 2014, a total of 120 hypertension patients complicated with elevated LDL-C were selected in the Department of Geriatrics, the Affiliated Hospital Hospital of Inner Mongolia Medical University, and they were randomly divided into control group and observation group, each of 60 cases. Patients of the two groups were given conventional treatment after admission, meanwhile patients of control group were given extra atorvastatin, while patients of observation group were given extra rosuvastatin calcium tablets ; patients of the two groups were treated till the end of the follow - up. Patients of the two groups were followed up for 2 years, blood liquids index （including TC, TG, LDL-C and HDL-C） , carotid intima media thickness （CIMT） and GFR before and after treatment were compared between the two groups. Results No statistically significant differences of TC, TG, LDL-C or HDL-C was found between the two groups before treatment （ P 〉 0. 05 ）. After treatment, TC and LDL-C of observation group were statistically significantly lower than those of control group, HDL-C of observation group was statistically significantly higher than that of control group （P 〈 0. 05 ）, while no statistically significant differences of TG was found between the two groups （ P 〉 0.05 ）. No statistically significant differences of CIMT or GFR was found between tile two groups before treatment （ P 〉 0. 05 ） ; after treatment, CIMT of observation group was statistically significantly lower than that of control group, while GFR of observation group was statistically significantly higher than that of control group （P 〈0. 05）. Conclusion Rosuvastatin has better clinical effect in treating hypertension patients complicated with elevated LDL-C than atorvastatin, can more effectively adjust the blood lipid metabolism, reduce the CIMT and improve the GFR, has better protective effect on target organ function.